A small healthcare company that remained largely unnoticed for years is now garnering attention thanks to its strong financial growth. Mumbai-based One Global Service Provider Limited has quietly transformed its business and become one of the fastest-growing names in the small-cap healthcare space. Its latest financial results show sharp increases in both revenue and profit, making it a key investor focus.
Over the past five years, the company has delivered robust returns to its shareholders. From a price of approximately ₹2 per share in January 2021, the stock has reached approximately ₹665, a massive gain of approximately 33,150%. At its peak level of ₹790, the returns are even more impressive.
This means that an investment of ₹1 lakh made five years ago would now be worth approximately ₹3.3 crore, and at the highest level, close to ₹3.95 crore. Such growth is rare, especially among smaller companies in the healthcare segment, and reflects strong business expansion rather than mere market speculation.
The company’s financial numbers reflect its rapid growth. Revenue from operations has increased from just ₹4 crore in FY21 to ₹498 crore in FY26, representing an increase of over 12,000 percent. This is not just consistent growth, but rapid growth in a short period of time.
Operating profit has also increased from ₹2 crore to ₹93 crore, while margins have improved to 19 percent. During this same period, net profit increased from ₹2 crore to ₹70 crore, representing a robust growth of nearly 3,400 percent.
In just one year, from FY25 to FY26, revenue increased from ₹147 crore to ₹498 crore. Net profit increased from ₹18 crore to ₹70 crore, representing nearly fourfold growth, clearly indicating strong execution and high demand.
A key reason for investor confidence is the company’s clean financial structure. Unlike many growing companies, it has virtually no debt, with long-term borrowings of only ₹0.03 crore as of March 2026.
The company funded its expansion from internal profits, increasing total equity from ₹71.72 crore to ₹141.23 crore. Reserves also increased significantly to ₹121.69 crore. However, trade receivables increased to ₹216.58 crore, which may require close monitoring as the business grows further.
The company also announced a final dividend of ₹1 per share for FY26, equivalent to a 10% payout on its face value of ₹10. While the dividend amount is small, it reflects management’s confidence in regular cash generation.
Overall, the company’s strong financial growth, debt-free status, and growing demand for healthcare services have created a strong base for future expansion. The key question now is whether it can maintain this high growth rate, but for now, the numbers show a positive outlook.
About The Company
Started in 1992 and formerly known as Overseas Synthetics Limited, the company has shifted its focus entirely to healthcare and life sciences. Today, it operates under the 1Global brand and serves hospitals and institutions worldwide in diagnostics, mass screening, and healthcare solutions.
The company’s business model focuses on providing end-to-end healthcare solutions, allowing it to serve both large institutions and the broader diagnostics ecosystem. This strategic shift has helped it capitalize on the growing global demand for healthcare services, especially with the increased focus on healthcare infrastructure.
Disclaimer: All the information provided in this article is for educational purposes only. We are NOT a SEBI registered investment advisor. DateUpdateGo always advises seeking guidance from a certified financial advisor before making any investment-related decisions.
